Gritstone Oncology (NASDAQ:GRTS) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.
Valuation and Earnings
This table compares Gritstone Oncology and Solid Biosciences’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Gritstone Oncology||$1.19 million||234.49||-$64.78 million||($7.26)||-1.07|
|Solid Biosciences||N/A||N/A||-$74.80 million||($2.25)||-4.90|
This table compares Gritstone Oncology and Solid Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings for Gritstone Oncology and Solid Biosciences, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Gritstone Oncology currently has a consensus price target of $21.25, suggesting a potential upside of 172.44%. Solid Biosciences has a consensus price target of $10.50, suggesting a potential downside of 4.81%. Given Gritstone Oncology’s stronger consensus rating and higher possible upside, analysts plainly believe Gritstone Oncology is more favorable than Solid Biosciences.
Institutional and Insider Ownership
77.7% of Gritstone Oncology shares are held by institutional investors. Comparatively, 45.7% of Solid Biosciences shares are held by institutional investors. 38.0% of Gritstone Oncology shares are held by insiders. Comparatively, 31.2% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Gritstone Oncology has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500.
Gritstone Oncology beats Solid Biosciences on 10 of the 13 factors compared between the two stocks.
Gritstone Oncology Company Profile
Gritstone Oncology Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.
Solid Biosciences Company Profile
Solid Biosciences Inc., a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a monoclonal antibody that is in preclinical trials to reduce fibrosis and inflammation. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits to DMD patients. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.